NS Partners Ltd Trims Holdings in IDEXX Laboratories, Inc. $IDXX

NS Partners Ltd trimmed its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 17.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,950 shares of the company’s stock after selling 6,261 shares during the quarter. NS Partners Ltd’s holdings in IDEXX Laboratories were worth $15,240,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $26,000. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the third quarter valued at approximately $26,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC increased its holdings in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the period. Finally, Wormser Freres Gestion lifted its stake in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IDXX. Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. UBS Group lifted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, Barclays lowered their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Stock Up 0.3%

IDXX opened at $556.69 on Tuesday. The company has a market cap of $43.86 billion, a P/E ratio of 39.15, a P/E/G ratio of 2.96 and a beta of 1.54. The business’s 50-day moving average price is $559.23 and its 200-day moving average price is $572.70. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period last year, the company earned $3.50 EPS. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.